Illumina (ILMN)

NASDAQ:ILMN

ILMN

Illumina

RESEARCH TOOLSreports

Want to see ILMN full AI Analyst Report?

Illumina (ILMN) Earnings Dates, Call Summary & Reports

Q: When does Illumina (ILMN) report earnings?

Illumina (ILMN) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).

Q: What is Illumina (ILMN) earnings time?

Illumina (ILMN) earnings time is at Aug 06, 2026, After Close (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Q: What is ILMN EPS forecast?

ILMN EPS forecast for the fiscal quarter 2026 (Q2) is 1.23.

4,636 Followers

Earnings Data

Report Date

Aug 06, 2026

After Close (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

1.23

Last Year’s EPS

1.19

Same Quarter Last Year

Analyst Consensus

Hold

Based on 12 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:Apr 30, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presented a clear beat in Q1 with multiple key operational and financial positives: revenue and EPS outperformance, strong clinical consumables growth (~20% ex-China), robust NovaSeq X placements (80+ in the quarter), margin expansion, and an upwardly revised full-year guide. Offsetting items include continued weakness in research & applied consumables (down ~12% ex-China), a 20% decline in microarrays RoW organic, supply constraints on NovaSeq X that require scaling investments, and near-term inflationary pressures impacting Q2 margins. Management framed the negatives as transitory or manageable and emphasized product innovation, strong cash flow, and progress toward 2027 targets.

Company Guidance

Illumina raised its 2026 outlook, increasing reported revenue to $4.52–$4.62B (up $20M), with acquired revenue expected to add 1.5–2 points and currency ~1%, and guiding Rest‑of‑World organic growth toward the high end of its prior 2–4% range. Management expects RoW organic sequencing consumables to grow low‑ to‑mid single digits (clinical double‑digit to mid‑teens; research & applied down mid‑ to‑high single digits), raised instruments guidance to flat‑to‑low‑single‑digit growth, and provided Q2 guidance of $1.12–$1.14B revenue, RoW organic +4–6%, and non‑GAAP EPS $1.20–$1.25. Profitability was lifted: full‑year non‑GAAP operating margin now 23.4–23.6% (Q2 ~22%), non‑GAAP diluted EPS $5.15–$5.30 (top and bottom raised $0.10; Q1 non‑GAAP EPS was $1.15 on $1.09B revenue), with management expecting ~350 bps margin expansion by end‑2026 excluding acquisitions (on the path to a 500 bps target by 2027). Operationally, Illumina placed >80 NovaSeq X units in Q1 (82% of volumes and 55% of revenue transitioned to X; 90% of research volume on X; 76% of clinical volume on X, targeting 80–85% by year‑end), reported sequencing GB output >30% YoY, Q1 free cash flow $251M, cash ≈$1.16B, gross leverage ≈1.5x, closed SomaLogic for ~$363M, and authorized an additional $1.5B of buybacks.

Top-Line Beat and Raised Full-Year Guidance

Q1 revenue of $1.09 billion, up 4.8% year-over-year (1.2% organic); came in $20 million above the midpoint of guidance. Company raised 2026 revenue guidance by $20 million to $4.52B–$4.62B and nudged EPS and margin guidance higher.

Strong Sequencing Consumables and Clinical Demand

Sequencing consumables revenue of $726 million, up 4% YoY; Rest of World organic consumables growth ~5%. Clinical consumables grew ~20% ex-China for the second consecutive quarter and represented >65% of sequencing consumables revenue in Q1.

Robust NovaSeq X Placements and Installed-Base Transition

Over 80 NovaSeq X placements in Q1 (~20 more than Q1 2025). As of Q1 roughly 82% of volumes and 55% of revenue transitioned to NovaSeq X; 90% of research & applied volume and 76% of clinical volume now on X with target of 80–85% clinical on X by end of 2026.

Sequencing Throughput and Instrument Momentum

Total sequencing GB output on connected high- and mid-throughput instruments grew >30% YoY. Sequencing instruments revenue was $118 million, up 9% YoY (Rest of World organic instrument growth ~10%).

Margin and EPS Expansion

Non‑GAAP gross margin of 68.2% (up ~80 bps YoY). Non‑GAAP operating margin 21.9% (expanding ~150 bps YoY). Non‑GAAP diluted EPS of $1.15 in Q1, up ~19% YoY and ~$0.10 above guidance midpoint. Full-year operating margin guidance raised to 23.4%–23.6%.

Strong Cash Generation and Capital Allocation

Cash flow from operations $289 million; free cash flow $251 million in Q1. Repurchased 2 million shares for $242 million; board authorized an additional $1.5 billion share repurchase program. Ending cash and equivalents ~$1.16 billion; gross leverage ~1.5x gross debt to LTM EBITDA.

Strategic M&A and Product Innovation

Closed SomaLogic acquisition (net cash payment ~$363 million); business performing in line with expectations. Product and R&D progress: TruePath launch (WGS with ~10 minutes hands-on prep), spatial transcriptomics early access with planned launch later in 2026, 18‑month NovaSeq X roadmap (14B and 35B flow cells, staggered runs, Q70 improvements), and BioInsight/billion cell atlas program.

Improving Long-Range Trajectory

Management reiterated pathway to high single-digit revenue growth, continued margin expansion (~350 bps implied by end of 2026 ex-acquisitions) and double-digit to teens EPS growth toward 2027 targets, reflecting confidence after Q1 outperformance.

Illumina (ILMN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ILMN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 06, 2026	2026 (Q2)	1.23 / -	1.19	―	―	―
Apr 30, 2026	2026 (Q1)	1.05 / 1.15	0.97	18.56% (+0.18)
Feb 05, 2026	2025 (Q4)	1.24 / 1.35	0.95	42.11% (+0.40)
Oct 30, 2025	2025 (Q3)	1.17 / 1.34	1.14	17.54% (+0.20)
Jul 31, 2025	2025 (Q2)	1.01 / 1.19	0.36	230.56% (+0.83)
May 08, 2025	2025 (Q1)	0.94 / 0.97	0.087	1014.94% (+0.88)
Feb 06, 2025	2024 (Q4)	0.91 / 0.95	0.136	598.53% (+0.81)
Nov 04, 2024	2024 (Q3)	0.88 / 1.14	0.321	255.14% (+0.82)
Aug 06, 2024	2024 (Q2)	0.11 / 0.36	0.311	15.76% (+0.05)
May 02, 2024	2024 (Q1)	0.04 / 0.09	0.078	11.54% (<+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ILMN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 30, 2026	$126.74	$135.78	+7.13%
Feb 05, 2026	$133.61	$119.72	-10.40%
Oct 30, 2025	$99.01	$123.54	+24.78%
Jul 31, 2025	$102.71	$94.66	-7.84%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.